Global Peptide Cancer Vaccine Supply, Demand and Key Producers, 2026-2032
The global Peptide Cancer Vaccine market size is expected to reach $ million by 2032, rising at a market growth of 19.3% CAGR during the forecast period (2026-2032).
Peptide cancer vaccines are innovative immunotherapy products designed based on specific tumor-associated antigen peptides. By delivering selected peptide sequences into patients, these vaccines activate T cells within the immune system to recognize and attack tumor cells, achieving targeted anti-cancer effects. Compared to traditional therapies, peptide vaccines offer strong specificity, low side effects, and ease of production, and can be combined with other immunotherapies or chemotherapies to enhance treatment efficacy. With advancements in molecular biology and immunology, peptide cancer vaccines demonstrate broad potential in personalized treatments and applications across multiple tumor types, marking a significant breakthrough and emerging trend in the field of tumor immunotherapy.
The global increase in cancer patient populations drives strong demand for effective, safe, and personalized treatment solutions. Annual reports from leading biopharmaceutical companies highlight intensified investments in peptide cancer vaccine R&D, fostering technological innovation and clinical trial progress to strengthen market competitiveness. Governments worldwide support innovative medical technologies through policies and funding, accelerating peptide vaccine development and commercialization. The strong specificity and combinational therapy potential of peptide vaccines meet diverse needs across cancer types and patient populations, especially demonstrating value in refractory and recurrent tumors. The widespread adoption of precision medicine concepts and advances in bioinformatics-aided design further enhance R&D efficiency and market penetration.
The peptide cancer vaccine market faces challenges including high technical complexity, lengthy development cycles, and stringent clinical validation requirements. Regulatory policies and approval processes vary across countries and regions, increasing difficulty and cost for international market expansion. Market competition intensifies amid coexistence of traditional therapies and multiple emerging immunotherapies, requiring continuous innovation to maintain leadership. High R&D investment and production costs limit participation of some small and medium enterprises and broader product accessibility. Uncertainties in efficacy and safety necessitate strengthened clinical data support and risk management to ensure market acceptance and long-term competitiveness.
Future downstream demand for peptide cancer vaccines will exhibit personalization, diversification, and integration. Major comprehensive hospitals and oncology centers serve as primary markets, emphasizing treatment efficacy, safety, and synergy with existing therapies. Patient demand for precise and low-side-effect innovative treatments fuels rapid growth in personalized peptide vaccine customization and combination therapies. Advances in companion diagnostics and biomarkers enable more precise patient matching, maximizing therapeutic outcomes. Suppliers must continually enhance R&D capabilities and service quality to meet complex and evolving clinical needs and regulatory environments.
This report studies the global Peptide Cancer Vaccine demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Peptide Cancer Vaccine, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Peptide Cancer Vaccine that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Peptide Cancer Vaccine total market, 2021-2032, (USD Million)
Global Peptide Cancer Vaccine total market by region & country, CAGR, 2021-2032, (USD Million)
U.S. VS China: Peptide Cancer Vaccine total market, key domestic companies, and share, (USD Million)
Global Peptide Cancer Vaccine revenue by player, revenue and market share 2021-2026, (USD Million)
Global Peptide Cancer Vaccine total market by Pipeline, CAGR, 2021-2032, (USD Million)
Global Peptide Cancer Vaccine total market by Application, CAGR, 2021-2032, (USD Million)
This report profiles major players in the global Peptide Cancer Vaccine market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Boston Biomedical, Ultimovacs, BrightPath Biotherapeutics, TapImmune, Immatics, Sellas, Imugene, VAXON Biotech, Generex Biotechnology, ISA Pharmaceuticals, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Peptide Cancer Vaccine market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Pipeline, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Peptide Cancer Vaccine Market, By Region:
1. How big is the global Peptide Cancer Vaccine market?
2. What is the demand of the global Peptide Cancer Vaccine market?
3. What is the year over year growth of the global Peptide Cancer Vaccine market?
4. What is the total value of the global Peptide Cancer Vaccine market?
5. Who are the Major Players in the global Peptide Cancer Vaccine market?
6. What are the growth factors driving the market demand?
Peptide cancer vaccines are innovative immunotherapy products designed based on specific tumor-associated antigen peptides. By delivering selected peptide sequences into patients, these vaccines activate T cells within the immune system to recognize and attack tumor cells, achieving targeted anti-cancer effects. Compared to traditional therapies, peptide vaccines offer strong specificity, low side effects, and ease of production, and can be combined with other immunotherapies or chemotherapies to enhance treatment efficacy. With advancements in molecular biology and immunology, peptide cancer vaccines demonstrate broad potential in personalized treatments and applications across multiple tumor types, marking a significant breakthrough and emerging trend in the field of tumor immunotherapy.
The global increase in cancer patient populations drives strong demand for effective, safe, and personalized treatment solutions. Annual reports from leading biopharmaceutical companies highlight intensified investments in peptide cancer vaccine R&D, fostering technological innovation and clinical trial progress to strengthen market competitiveness. Governments worldwide support innovative medical technologies through policies and funding, accelerating peptide vaccine development and commercialization. The strong specificity and combinational therapy potential of peptide vaccines meet diverse needs across cancer types and patient populations, especially demonstrating value in refractory and recurrent tumors. The widespread adoption of precision medicine concepts and advances in bioinformatics-aided design further enhance R&D efficiency and market penetration.
The peptide cancer vaccine market faces challenges including high technical complexity, lengthy development cycles, and stringent clinical validation requirements. Regulatory policies and approval processes vary across countries and regions, increasing difficulty and cost for international market expansion. Market competition intensifies amid coexistence of traditional therapies and multiple emerging immunotherapies, requiring continuous innovation to maintain leadership. High R&D investment and production costs limit participation of some small and medium enterprises and broader product accessibility. Uncertainties in efficacy and safety necessitate strengthened clinical data support and risk management to ensure market acceptance and long-term competitiveness.
Future downstream demand for peptide cancer vaccines will exhibit personalization, diversification, and integration. Major comprehensive hospitals and oncology centers serve as primary markets, emphasizing treatment efficacy, safety, and synergy with existing therapies. Patient demand for precise and low-side-effect innovative treatments fuels rapid growth in personalized peptide vaccine customization and combination therapies. Advances in companion diagnostics and biomarkers enable more precise patient matching, maximizing therapeutic outcomes. Suppliers must continually enhance R&D capabilities and service quality to meet complex and evolving clinical needs and regulatory environments.
This report studies the global Peptide Cancer Vaccine demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Peptide Cancer Vaccine, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Peptide Cancer Vaccine that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Peptide Cancer Vaccine total market, 2021-2032, (USD Million)
Global Peptide Cancer Vaccine total market by region & country, CAGR, 2021-2032, (USD Million)
U.S. VS China: Peptide Cancer Vaccine total market, key domestic companies, and share, (USD Million)
Global Peptide Cancer Vaccine revenue by player, revenue and market share 2021-2026, (USD Million)
Global Peptide Cancer Vaccine total market by Pipeline, CAGR, 2021-2032, (USD Million)
Global Peptide Cancer Vaccine total market by Application, CAGR, 2021-2032, (USD Million)
This report profiles major players in the global Peptide Cancer Vaccine market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Boston Biomedical, Ultimovacs, BrightPath Biotherapeutics, TapImmune, Immatics, Sellas, Imugene, VAXON Biotech, Generex Biotechnology, ISA Pharmaceuticals, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Peptide Cancer Vaccine market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Pipeline, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Peptide Cancer Vaccine Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- ITK-1
- GRN-1201
- TPIV200
- TPIV110
- UV1
- Galinpepimut-S
- TARP 27-35
- HER-Vaxx
- Vx-001
- Others
- Breast Cancer
- Lung Cancer
- Melanoma
- Prostate Cancer
- Others
- Boston Biomedical
- Ultimovacs
- BrightPath Biotherapeutics
- TapImmune
- Immatics
- Sellas
- Imugene
- VAXON Biotech
- Generex Biotechnology
- ISA Pharmaceuticals
- OncoTherapy Science
1. How big is the global Peptide Cancer Vaccine market?
2. What is the demand of the global Peptide Cancer Vaccine market?
3. What is the year over year growth of the global Peptide Cancer Vaccine market?
4. What is the total value of the global Peptide Cancer Vaccine market?
5. Who are the Major Players in the global Peptide Cancer Vaccine market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Peptide Cancer Vaccine Introduction
1.2 World Peptide Cancer Vaccine Market Size & Forecast (2021 & 2025 & 2032)
1.3 World Peptide Cancer Vaccine Total Market by Region (by Headquarter Location)
1.3.1 World Peptide Cancer Vaccine Market Size by Region (2021-2032), (by Headquarter Location)
1.3.2 United States Based Company Peptide Cancer Vaccine Revenue (2021-2032)
1.3.3 China Based Company Peptide Cancer Vaccine Revenue (2021-2032)
1.3.4 Europe Based Company Peptide Cancer Vaccine Revenue (2021-2032)
1.3.5 Japan Based Company Peptide Cancer Vaccine Revenue (2021-2032)
1.3.6 South Korea Based Company Peptide Cancer Vaccine Revenue (2021-2032)
1.3.7 ASEAN Based Company Peptide Cancer Vaccine Revenue (2021-2032)
1.3.8 India Based Company Peptide Cancer Vaccine Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Peptide Cancer Vaccine Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Major Market Trends
2 DEMAND SUMMARY
2.1 World Peptide Cancer Vaccine Consumption Value (2021-2032)
2.2 World Peptide Cancer Vaccine Consumption Value by Region
2.2.1 World Peptide Cancer Vaccine Consumption Value by Region (2021-2026)
2.2.2 World Peptide Cancer Vaccine Consumption Value Forecast by Region (2027-2032)
2.3 United States Peptide Cancer Vaccine Consumption Value (2021-2032)
2.4 China Peptide Cancer Vaccine Consumption Value (2021-2032)
2.5 Europe Peptide Cancer Vaccine Consumption Value (2021-2032)
2.6 Japan Peptide Cancer Vaccine Consumption Value (2021-2032)
2.7 South Korea Peptide Cancer Vaccine Consumption Value (2021-2032)
2.8 ASEAN Peptide Cancer Vaccine Consumption Value (2021-2032)
2.9 India Peptide Cancer Vaccine Consumption Value (2021-2032)
3 WORLD PEPTIDE CANCER VACCINE COMPANIES COMPETITIVE ANALYSIS
3.1 World Peptide Cancer Vaccine Revenue by Player (2021-2026)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Peptide Cancer Vaccine Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Peptide Cancer Vaccine in 2025
3.2.3 Global Concentration Ratios (CR8) for Peptide Cancer Vaccine in 2025
3.3 Peptide Cancer Vaccine Company Evaluation Quadrant
3.4 Peptide Cancer Vaccine Market: Overall Company Footprint Analysis
3.4.1 Peptide Cancer Vaccine Market: Region Footprint
3.4.2 Peptide Cancer Vaccine Market: Company Product Type Footprint
3.4.3 Peptide Cancer Vaccine Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Peptide Cancer Vaccine Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Peptide Cancer Vaccine Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
4.1.2 United States VS China: Peptide Cancer Vaccine Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: Peptide Cancer Vaccine Consumption Value Comparison
4.2.1 United States VS China: Peptide Cancer Vaccine Consumption Value Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Peptide Cancer Vaccine Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based Peptide Cancer Vaccine Companies and Market Share, 2021-2026
4.3.1 United States Based Peptide Cancer Vaccine Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Peptide Cancer Vaccine Revenue, (2021-2026)
4.4 China Based Companies Peptide Cancer Vaccine Revenue and Market Share, 2021-2026
4.4.1 China Based Peptide Cancer Vaccine Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Peptide Cancer Vaccine Revenue, (2021-2026)
4.5 Rest of World Based Peptide Cancer Vaccine Companies and Market Share, 2021-2026
4.5.1 Rest of World Based Peptide Cancer Vaccine Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies Peptide Cancer Vaccine Revenue (2021-2026)
5 MARKET ANALYSIS BY PIPELINE
5.1 World Peptide Cancer Vaccine Market Size Overview by Pipeline: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Pipeline
5.2.1 ITK-1
5.2.2 GRN-1201
5.2.3 TPIV200
5.2.4 TPIV110
5.2.5 UV1
5.2.6 Galinpepimut-S
5.2.7 TARP 27-35
5.2.8 HER-Vaxx
5.2.9 Vx-001
5.3 Market Segment by Pipeline
5.3.1 World Peptide Cancer Vaccine Market Size by Pipeline (2021-2026)
5.3.2 World Peptide Cancer Vaccine Market Size by Pipeline (2027-2032)
5.3.3 World Peptide Cancer Vaccine Market Size Market Share by Pipeline (2027-2032)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Peptide Cancer Vaccine Market Size Overview by Application: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Application
6.2.1 Breast Cancer
6.2.2 Lung Cancer
6.2.3 Melanoma
6.2.4 Prostate Cancer
6.2.5 Others
6.3 Market Segment by Application
6.3.1 World Peptide Cancer Vaccine Market Size by Application (2021-2026)
6.3.2 World Peptide Cancer Vaccine Market Size by Application (2027-2032)
6.3.3 World Peptide Cancer Vaccine Market Size Market Share by Application (2021-2032)
7 COMPANY PROFILES
7.1 Boston Biomedical
7.1.1 Boston Biomedical Details
7.1.2 Boston Biomedical Major Business
7.1.3 Boston Biomedical Peptide Cancer Vaccine Product and Services
7.1.4 Boston Biomedical Peptide Cancer Vaccine Revenue, Gross Margin and Market Share (2021-2026)
7.1.5 Boston Biomedical Recent Developments/Updates
7.1.6 Boston Biomedical Competitive Strengths & Weaknesses
7.2 Ultimovacs
7.2.1 Ultimovacs Details
7.2.2 Ultimovacs Major Business
7.2.3 Ultimovacs Peptide Cancer Vaccine Product and Services
7.2.4 Ultimovacs Peptide Cancer Vaccine Revenue, Gross Margin and Market Share (2021-2026)
7.2.5 Ultimovacs Recent Developments/Updates
7.2.6 Ultimovacs Competitive Strengths & Weaknesses
7.3 BrightPath Biotherapeutics
7.3.1 BrightPath Biotherapeutics Details
7.3.2 BrightPath Biotherapeutics Major Business
7.3.3 BrightPath Biotherapeutics Peptide Cancer Vaccine Product and Services
7.3.4 BrightPath Biotherapeutics Peptide Cancer Vaccine Revenue, Gross Margin and Market Share (2021-2026)
7.3.5 BrightPath Biotherapeutics Recent Developments/Updates
7.3.6 BrightPath Biotherapeutics Competitive Strengths & Weaknesses
7.4 TapImmune
7.4.1 TapImmune Details
7.4.2 TapImmune Major Business
7.4.3 TapImmune Peptide Cancer Vaccine Product and Services
7.4.4 TapImmune Peptide Cancer Vaccine Revenue, Gross Margin and Market Share (2021-2026)
7.4.5 TapImmune Recent Developments/Updates
7.4.6 TapImmune Competitive Strengths & Weaknesses
7.5 Immatics
7.5.1 Immatics Details
7.5.2 Immatics Major Business
7.5.3 Immatics Peptide Cancer Vaccine Product and Services
7.5.4 Immatics Peptide Cancer Vaccine Revenue, Gross Margin and Market Share (2021-2026)
7.5.5 Immatics Recent Developments/Updates
7.5.6 Immatics Competitive Strengths & Weaknesses
7.6 Sellas
7.6.1 Sellas Details
7.6.2 Sellas Major Business
7.6.3 Sellas Peptide Cancer Vaccine Product and Services
7.6.4 Sellas Peptide Cancer Vaccine Revenue, Gross Margin and Market Share (2021-2026)
7.6.5 Sellas Recent Developments/Updates
7.6.6 Sellas Competitive Strengths & Weaknesses
7.7 Imugene
7.7.1 Imugene Details
7.7.2 Imugene Major Business
7.7.3 Imugene Peptide Cancer Vaccine Product and Services
7.7.4 Imugene Peptide Cancer Vaccine Revenue, Gross Margin and Market Share (2021-2026)
7.7.5 Imugene Recent Developments/Updates
7.7.6 Imugene Competitive Strengths & Weaknesses
7.8 VAXON Biotech
7.8.1 VAXON Biotech Details
7.8.2 VAXON Biotech Major Business
7.8.3 VAXON Biotech Peptide Cancer Vaccine Product and Services
7.8.4 VAXON Biotech Peptide Cancer Vaccine Revenue, Gross Margin and Market Share (2021-2026)
7.8.5 VAXON Biotech Recent Developments/Updates
7.8.6 VAXON Biotech Competitive Strengths & Weaknesses
7.9 Generex Biotechnology
7.9.1 Generex Biotechnology Details
7.9.2 Generex Biotechnology Major Business
7.9.3 Generex Biotechnology Peptide Cancer Vaccine Product and Services
7.9.4 Generex Biotechnology Peptide Cancer Vaccine Revenue, Gross Margin and Market Share (2021-2026)
7.9.5 Generex Biotechnology Recent Developments/Updates
7.9.6 Generex Biotechnology Competitive Strengths & Weaknesses
7.10 ISA Pharmaceuticals
7.10.1 ISA Pharmaceuticals Details
7.10.2 ISA Pharmaceuticals Major Business
7.10.3 ISA Pharmaceuticals Peptide Cancer Vaccine Product and Services
7.10.4 ISA Pharmaceuticals Peptide Cancer Vaccine Revenue, Gross Margin and Market Share (2021-2026)
7.10.5 ISA Pharmaceuticals Recent Developments/Updates
7.10.6 ISA Pharmaceuticals Competitive Strengths & Weaknesses
7.11 OncoTherapy Science
7.11.1 OncoTherapy Science Details
7.11.2 OncoTherapy Science Major Business
7.11.3 OncoTherapy Science Peptide Cancer Vaccine Product and Services
7.11.4 OncoTherapy Science Peptide Cancer Vaccine Revenue, Gross Margin and Market Share (2021-2026)
7.11.5 OncoTherapy Science Recent Developments/Updates
7.11.6 OncoTherapy Science Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Peptide Cancer Vaccine Industry Chain
8.2 Peptide Cancer Vaccine Upstream Analysis
8.3 Peptide Cancer Vaccine Midstream Analysis
8.4 Peptide Cancer Vaccine Downstream Analysis
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
1.1 Peptide Cancer Vaccine Introduction
1.2 World Peptide Cancer Vaccine Market Size & Forecast (2021 & 2025 & 2032)
1.3 World Peptide Cancer Vaccine Total Market by Region (by Headquarter Location)
1.3.1 World Peptide Cancer Vaccine Market Size by Region (2021-2032), (by Headquarter Location)
1.3.2 United States Based Company Peptide Cancer Vaccine Revenue (2021-2032)
1.3.3 China Based Company Peptide Cancer Vaccine Revenue (2021-2032)
1.3.4 Europe Based Company Peptide Cancer Vaccine Revenue (2021-2032)
1.3.5 Japan Based Company Peptide Cancer Vaccine Revenue (2021-2032)
1.3.6 South Korea Based Company Peptide Cancer Vaccine Revenue (2021-2032)
1.3.7 ASEAN Based Company Peptide Cancer Vaccine Revenue (2021-2032)
1.3.8 India Based Company Peptide Cancer Vaccine Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Peptide Cancer Vaccine Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Major Market Trends
2 DEMAND SUMMARY
2.1 World Peptide Cancer Vaccine Consumption Value (2021-2032)
2.2 World Peptide Cancer Vaccine Consumption Value by Region
2.2.1 World Peptide Cancer Vaccine Consumption Value by Region (2021-2026)
2.2.2 World Peptide Cancer Vaccine Consumption Value Forecast by Region (2027-2032)
2.3 United States Peptide Cancer Vaccine Consumption Value (2021-2032)
2.4 China Peptide Cancer Vaccine Consumption Value (2021-2032)
2.5 Europe Peptide Cancer Vaccine Consumption Value (2021-2032)
2.6 Japan Peptide Cancer Vaccine Consumption Value (2021-2032)
2.7 South Korea Peptide Cancer Vaccine Consumption Value (2021-2032)
2.8 ASEAN Peptide Cancer Vaccine Consumption Value (2021-2032)
2.9 India Peptide Cancer Vaccine Consumption Value (2021-2032)
3 WORLD PEPTIDE CANCER VACCINE COMPANIES COMPETITIVE ANALYSIS
3.1 World Peptide Cancer Vaccine Revenue by Player (2021-2026)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Peptide Cancer Vaccine Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Peptide Cancer Vaccine in 2025
3.2.3 Global Concentration Ratios (CR8) for Peptide Cancer Vaccine in 2025
3.3 Peptide Cancer Vaccine Company Evaluation Quadrant
3.4 Peptide Cancer Vaccine Market: Overall Company Footprint Analysis
3.4.1 Peptide Cancer Vaccine Market: Region Footprint
3.4.2 Peptide Cancer Vaccine Market: Company Product Type Footprint
3.4.3 Peptide Cancer Vaccine Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Peptide Cancer Vaccine Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Peptide Cancer Vaccine Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
4.1.2 United States VS China: Peptide Cancer Vaccine Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: Peptide Cancer Vaccine Consumption Value Comparison
4.2.1 United States VS China: Peptide Cancer Vaccine Consumption Value Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Peptide Cancer Vaccine Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based Peptide Cancer Vaccine Companies and Market Share, 2021-2026
4.3.1 United States Based Peptide Cancer Vaccine Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Peptide Cancer Vaccine Revenue, (2021-2026)
4.4 China Based Companies Peptide Cancer Vaccine Revenue and Market Share, 2021-2026
4.4.1 China Based Peptide Cancer Vaccine Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Peptide Cancer Vaccine Revenue, (2021-2026)
4.5 Rest of World Based Peptide Cancer Vaccine Companies and Market Share, 2021-2026
4.5.1 Rest of World Based Peptide Cancer Vaccine Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies Peptide Cancer Vaccine Revenue (2021-2026)
5 MARKET ANALYSIS BY PIPELINE
5.1 World Peptide Cancer Vaccine Market Size Overview by Pipeline: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Pipeline
5.2.1 ITK-1
5.2.2 GRN-1201
5.2.3 TPIV200
5.2.4 TPIV110
5.2.5 UV1
5.2.6 Galinpepimut-S
5.2.7 TARP 27-35
5.2.8 HER-Vaxx
5.2.9 Vx-001
5.3 Market Segment by Pipeline
5.3.1 World Peptide Cancer Vaccine Market Size by Pipeline (2021-2026)
5.3.2 World Peptide Cancer Vaccine Market Size by Pipeline (2027-2032)
5.3.3 World Peptide Cancer Vaccine Market Size Market Share by Pipeline (2027-2032)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Peptide Cancer Vaccine Market Size Overview by Application: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Application
6.2.1 Breast Cancer
6.2.2 Lung Cancer
6.2.3 Melanoma
6.2.4 Prostate Cancer
6.2.5 Others
6.3 Market Segment by Application
6.3.1 World Peptide Cancer Vaccine Market Size by Application (2021-2026)
6.3.2 World Peptide Cancer Vaccine Market Size by Application (2027-2032)
6.3.3 World Peptide Cancer Vaccine Market Size Market Share by Application (2021-2032)
7 COMPANY PROFILES
7.1 Boston Biomedical
7.1.1 Boston Biomedical Details
7.1.2 Boston Biomedical Major Business
7.1.3 Boston Biomedical Peptide Cancer Vaccine Product and Services
7.1.4 Boston Biomedical Peptide Cancer Vaccine Revenue, Gross Margin and Market Share (2021-2026)
7.1.5 Boston Biomedical Recent Developments/Updates
7.1.6 Boston Biomedical Competitive Strengths & Weaknesses
7.2 Ultimovacs
7.2.1 Ultimovacs Details
7.2.2 Ultimovacs Major Business
7.2.3 Ultimovacs Peptide Cancer Vaccine Product and Services
7.2.4 Ultimovacs Peptide Cancer Vaccine Revenue, Gross Margin and Market Share (2021-2026)
7.2.5 Ultimovacs Recent Developments/Updates
7.2.6 Ultimovacs Competitive Strengths & Weaknesses
7.3 BrightPath Biotherapeutics
7.3.1 BrightPath Biotherapeutics Details
7.3.2 BrightPath Biotherapeutics Major Business
7.3.3 BrightPath Biotherapeutics Peptide Cancer Vaccine Product and Services
7.3.4 BrightPath Biotherapeutics Peptide Cancer Vaccine Revenue, Gross Margin and Market Share (2021-2026)
7.3.5 BrightPath Biotherapeutics Recent Developments/Updates
7.3.6 BrightPath Biotherapeutics Competitive Strengths & Weaknesses
7.4 TapImmune
7.4.1 TapImmune Details
7.4.2 TapImmune Major Business
7.4.3 TapImmune Peptide Cancer Vaccine Product and Services
7.4.4 TapImmune Peptide Cancer Vaccine Revenue, Gross Margin and Market Share (2021-2026)
7.4.5 TapImmune Recent Developments/Updates
7.4.6 TapImmune Competitive Strengths & Weaknesses
7.5 Immatics
7.5.1 Immatics Details
7.5.2 Immatics Major Business
7.5.3 Immatics Peptide Cancer Vaccine Product and Services
7.5.4 Immatics Peptide Cancer Vaccine Revenue, Gross Margin and Market Share (2021-2026)
7.5.5 Immatics Recent Developments/Updates
7.5.6 Immatics Competitive Strengths & Weaknesses
7.6 Sellas
7.6.1 Sellas Details
7.6.2 Sellas Major Business
7.6.3 Sellas Peptide Cancer Vaccine Product and Services
7.6.4 Sellas Peptide Cancer Vaccine Revenue, Gross Margin and Market Share (2021-2026)
7.6.5 Sellas Recent Developments/Updates
7.6.6 Sellas Competitive Strengths & Weaknesses
7.7 Imugene
7.7.1 Imugene Details
7.7.2 Imugene Major Business
7.7.3 Imugene Peptide Cancer Vaccine Product and Services
7.7.4 Imugene Peptide Cancer Vaccine Revenue, Gross Margin and Market Share (2021-2026)
7.7.5 Imugene Recent Developments/Updates
7.7.6 Imugene Competitive Strengths & Weaknesses
7.8 VAXON Biotech
7.8.1 VAXON Biotech Details
7.8.2 VAXON Biotech Major Business
7.8.3 VAXON Biotech Peptide Cancer Vaccine Product and Services
7.8.4 VAXON Biotech Peptide Cancer Vaccine Revenue, Gross Margin and Market Share (2021-2026)
7.8.5 VAXON Biotech Recent Developments/Updates
7.8.6 VAXON Biotech Competitive Strengths & Weaknesses
7.9 Generex Biotechnology
7.9.1 Generex Biotechnology Details
7.9.2 Generex Biotechnology Major Business
7.9.3 Generex Biotechnology Peptide Cancer Vaccine Product and Services
7.9.4 Generex Biotechnology Peptide Cancer Vaccine Revenue, Gross Margin and Market Share (2021-2026)
7.9.5 Generex Biotechnology Recent Developments/Updates
7.9.6 Generex Biotechnology Competitive Strengths & Weaknesses
7.10 ISA Pharmaceuticals
7.10.1 ISA Pharmaceuticals Details
7.10.2 ISA Pharmaceuticals Major Business
7.10.3 ISA Pharmaceuticals Peptide Cancer Vaccine Product and Services
7.10.4 ISA Pharmaceuticals Peptide Cancer Vaccine Revenue, Gross Margin and Market Share (2021-2026)
7.10.5 ISA Pharmaceuticals Recent Developments/Updates
7.10.6 ISA Pharmaceuticals Competitive Strengths & Weaknesses
7.11 OncoTherapy Science
7.11.1 OncoTherapy Science Details
7.11.2 OncoTherapy Science Major Business
7.11.3 OncoTherapy Science Peptide Cancer Vaccine Product and Services
7.11.4 OncoTherapy Science Peptide Cancer Vaccine Revenue, Gross Margin and Market Share (2021-2026)
7.11.5 OncoTherapy Science Recent Developments/Updates
7.11.6 OncoTherapy Science Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Peptide Cancer Vaccine Industry Chain
8.2 Peptide Cancer Vaccine Upstream Analysis
8.3 Peptide Cancer Vaccine Midstream Analysis
8.4 Peptide Cancer Vaccine Downstream Analysis
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
LIST OF TABLES
Table 1. World Peptide Cancer Vaccine Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World Peptide Cancer Vaccine Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World Peptide Cancer Vaccine Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World Peptide Cancer Vaccine Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World Peptide Cancer Vaccine Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Peptide Cancer Vaccine Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World Peptide Cancer Vaccine Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World Peptide Cancer Vaccine Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World Peptide Cancer Vaccine Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key Peptide Cancer Vaccine Players in 2025
Table 12. World Peptide Cancer Vaccine Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global Peptide Cancer Vaccine Company Evaluation Quadrant
Table 14. Head Office of Key Peptide Cancer Vaccine Players
Table 15. Peptide Cancer Vaccine Market: Company Product Type Footprint
Table 16. Peptide Cancer Vaccine Market: Company Product Application Footprint
Table 17. Peptide Cancer Vaccine Mergers & Acquisitions Activity
Table 18. United States VS China Peptide Cancer Vaccine Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China Peptide Cancer Vaccine Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based Peptide Cancer Vaccine Companies, Headquarters (States, Country)
Table 21. United States Based Companies Peptide Cancer Vaccine Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies Peptide Cancer Vaccine Revenue Market Share (2021-2026)
Table 23. China Based Peptide Cancer Vaccine Companies, Headquarters (Province, Country)
Table 24. China Based Companies Peptide Cancer Vaccine Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies Peptide Cancer Vaccine Revenue Market Share (2021-2026)
Table 26. Rest of World Based Peptide Cancer Vaccine Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies Peptide Cancer Vaccine Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies Peptide Cancer Vaccine Revenue Market Share (2021-2026)
Table 29. World Peptide Cancer Vaccine Market Size by Pipeline, (USD Million), 2021 & 2025 & 2032
Table 30. World Peptide Cancer Vaccine Market Size Value by Pipeline (2021-2026) & (USD Million)
Table 31. World Peptide Cancer Vaccine Market Size by Pipeline (2027-2032) & (USD Million)
Table 32. World Peptide Cancer Vaccine Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 33. World Peptide Cancer Vaccine Market Size by Application (2021-2026) & (USD Million)
Table 34. World Peptide Cancer Vaccine Market Size by Application (2027-2032) & (USD Million)
Table 35. Boston Biomedical Basic Information, Manufacturing Base and Competitors
Table 36. Boston Biomedical Major Business
Table 37. Boston Biomedical Peptide Cancer Vaccine Product and Services
Table 38. Boston Biomedical Peptide Cancer Vaccine Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 39. Boston Biomedical Recent Developments/Updates
Table 40. Boston Biomedical Competitive Strengths & Weaknesses
Table 41. Ultimovacs Basic Information, Manufacturing Base and Competitors
Table 42. Ultimovacs Major Business
Table 43. Ultimovacs Peptide Cancer Vaccine Product and Services
Table 44. Ultimovacs Peptide Cancer Vaccine Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 45. Ultimovacs Recent Developments/Updates
Table 46. Ultimovacs Competitive Strengths & Weaknesses
Table 47. BrightPath Biotherapeutics Basic Information, Manufacturing Base and Competitors
Table 48. BrightPath Biotherapeutics Major Business
Table 49. BrightPath Biotherapeutics Peptide Cancer Vaccine Product and Services
Table 50. BrightPath Biotherapeutics Peptide Cancer Vaccine Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 51. BrightPath Biotherapeutics Recent Developments/Updates
Table 52. BrightPath Biotherapeutics Competitive Strengths & Weaknesses
Table 53. TapImmune Basic Information, Manufacturing Base and Competitors
Table 54. TapImmune Major Business
Table 55. TapImmune Peptide Cancer Vaccine Product and Services
Table 56. TapImmune Peptide Cancer Vaccine Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 57. TapImmune Recent Developments/Updates
Table 58. TapImmune Competitive Strengths & Weaknesses
Table 59. Immatics Basic Information, Manufacturing Base and Competitors
Table 60. Immatics Major Business
Table 61. Immatics Peptide Cancer Vaccine Product and Services
Table 62. Immatics Peptide Cancer Vaccine Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 63. Immatics Recent Developments/Updates
Table 64. Immatics Competitive Strengths & Weaknesses
Table 65. Sellas Basic Information, Manufacturing Base and Competitors
Table 66. Sellas Major Business
Table 67. Sellas Peptide Cancer Vaccine Product and Services
Table 68. Sellas Peptide Cancer Vaccine Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 69. Sellas Recent Developments/Updates
Table 70. Sellas Competitive Strengths & Weaknesses
Table 71. Imugene Basic Information, Manufacturing Base and Competitors
Table 72. Imugene Major Business
Table 73. Imugene Peptide Cancer Vaccine Product and Services
Table 74. Imugene Peptide Cancer Vaccine Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 75. Imugene Recent Developments/Updates
Table 76. Imugene Competitive Strengths & Weaknesses
Table 77. VAXON Biotech Basic Information, Manufacturing Base and Competitors
Table 78. VAXON Biotech Major Business
Table 79. VAXON Biotech Peptide Cancer Vaccine Product and Services
Table 80. VAXON Biotech Peptide Cancer Vaccine Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 81. VAXON Biotech Recent Developments/Updates
Table 82. VAXON Biotech Competitive Strengths & Weaknesses
Table 83. Generex Biotechnology Basic Information, Manufacturing Base and Competitors
Table 84. Generex Biotechnology Major Business
Table 85. Generex Biotechnology Peptide Cancer Vaccine Product and Services
Table 86. Generex Biotechnology Peptide Cancer Vaccine Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 87. Generex Biotechnology Recent Developments/Updates
Table 88. Generex Biotechnology Competitive Strengths & Weaknesses
Table 89. ISA Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 90. ISA Pharmaceuticals Major Business
Table 91. ISA Pharmaceuticals Peptide Cancer Vaccine Product and Services
Table 92. ISA Pharmaceuticals Peptide Cancer Vaccine Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 93. ISA Pharmaceuticals Recent Developments/Updates
Table 94. ISA Pharmaceuticals Competitive Strengths & Weaknesses
Table 95. OncoTherapy Science Basic Information, Manufacturing Base and Competitors
Table 96. OncoTherapy Science Major Business
Table 97. OncoTherapy Science Peptide Cancer Vaccine Product and Services
Table 98. OncoTherapy Science Peptide Cancer Vaccine Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 99. OncoTherapy Science Recent Developments/Updates
Table 100. OncoTherapy Science Competitive Strengths & Weaknesses
Table 101. Global Key Players of Peptide Cancer Vaccine Upstream (Raw Materials)
Table 102. Global Peptide Cancer Vaccine Typical Customers
Table 1. World Peptide Cancer Vaccine Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World Peptide Cancer Vaccine Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World Peptide Cancer Vaccine Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World Peptide Cancer Vaccine Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World Peptide Cancer Vaccine Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Peptide Cancer Vaccine Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World Peptide Cancer Vaccine Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World Peptide Cancer Vaccine Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World Peptide Cancer Vaccine Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key Peptide Cancer Vaccine Players in 2025
Table 12. World Peptide Cancer Vaccine Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global Peptide Cancer Vaccine Company Evaluation Quadrant
Table 14. Head Office of Key Peptide Cancer Vaccine Players
Table 15. Peptide Cancer Vaccine Market: Company Product Type Footprint
Table 16. Peptide Cancer Vaccine Market: Company Product Application Footprint
Table 17. Peptide Cancer Vaccine Mergers & Acquisitions Activity
Table 18. United States VS China Peptide Cancer Vaccine Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China Peptide Cancer Vaccine Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based Peptide Cancer Vaccine Companies, Headquarters (States, Country)
Table 21. United States Based Companies Peptide Cancer Vaccine Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies Peptide Cancer Vaccine Revenue Market Share (2021-2026)
Table 23. China Based Peptide Cancer Vaccine Companies, Headquarters (Province, Country)
Table 24. China Based Companies Peptide Cancer Vaccine Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies Peptide Cancer Vaccine Revenue Market Share (2021-2026)
Table 26. Rest of World Based Peptide Cancer Vaccine Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies Peptide Cancer Vaccine Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies Peptide Cancer Vaccine Revenue Market Share (2021-2026)
Table 29. World Peptide Cancer Vaccine Market Size by Pipeline, (USD Million), 2021 & 2025 & 2032
Table 30. World Peptide Cancer Vaccine Market Size Value by Pipeline (2021-2026) & (USD Million)
Table 31. World Peptide Cancer Vaccine Market Size by Pipeline (2027-2032) & (USD Million)
Table 32. World Peptide Cancer Vaccine Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 33. World Peptide Cancer Vaccine Market Size by Application (2021-2026) & (USD Million)
Table 34. World Peptide Cancer Vaccine Market Size by Application (2027-2032) & (USD Million)
Table 35. Boston Biomedical Basic Information, Manufacturing Base and Competitors
Table 36. Boston Biomedical Major Business
Table 37. Boston Biomedical Peptide Cancer Vaccine Product and Services
Table 38. Boston Biomedical Peptide Cancer Vaccine Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 39. Boston Biomedical Recent Developments/Updates
Table 40. Boston Biomedical Competitive Strengths & Weaknesses
Table 41. Ultimovacs Basic Information, Manufacturing Base and Competitors
Table 42. Ultimovacs Major Business
Table 43. Ultimovacs Peptide Cancer Vaccine Product and Services
Table 44. Ultimovacs Peptide Cancer Vaccine Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 45. Ultimovacs Recent Developments/Updates
Table 46. Ultimovacs Competitive Strengths & Weaknesses
Table 47. BrightPath Biotherapeutics Basic Information, Manufacturing Base and Competitors
Table 48. BrightPath Biotherapeutics Major Business
Table 49. BrightPath Biotherapeutics Peptide Cancer Vaccine Product and Services
Table 50. BrightPath Biotherapeutics Peptide Cancer Vaccine Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 51. BrightPath Biotherapeutics Recent Developments/Updates
Table 52. BrightPath Biotherapeutics Competitive Strengths & Weaknesses
Table 53. TapImmune Basic Information, Manufacturing Base and Competitors
Table 54. TapImmune Major Business
Table 55. TapImmune Peptide Cancer Vaccine Product and Services
Table 56. TapImmune Peptide Cancer Vaccine Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 57. TapImmune Recent Developments/Updates
Table 58. TapImmune Competitive Strengths & Weaknesses
Table 59. Immatics Basic Information, Manufacturing Base and Competitors
Table 60. Immatics Major Business
Table 61. Immatics Peptide Cancer Vaccine Product and Services
Table 62. Immatics Peptide Cancer Vaccine Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 63. Immatics Recent Developments/Updates
Table 64. Immatics Competitive Strengths & Weaknesses
Table 65. Sellas Basic Information, Manufacturing Base and Competitors
Table 66. Sellas Major Business
Table 67. Sellas Peptide Cancer Vaccine Product and Services
Table 68. Sellas Peptide Cancer Vaccine Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 69. Sellas Recent Developments/Updates
Table 70. Sellas Competitive Strengths & Weaknesses
Table 71. Imugene Basic Information, Manufacturing Base and Competitors
Table 72. Imugene Major Business
Table 73. Imugene Peptide Cancer Vaccine Product and Services
Table 74. Imugene Peptide Cancer Vaccine Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 75. Imugene Recent Developments/Updates
Table 76. Imugene Competitive Strengths & Weaknesses
Table 77. VAXON Biotech Basic Information, Manufacturing Base and Competitors
Table 78. VAXON Biotech Major Business
Table 79. VAXON Biotech Peptide Cancer Vaccine Product and Services
Table 80. VAXON Biotech Peptide Cancer Vaccine Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 81. VAXON Biotech Recent Developments/Updates
Table 82. VAXON Biotech Competitive Strengths & Weaknesses
Table 83. Generex Biotechnology Basic Information, Manufacturing Base and Competitors
Table 84. Generex Biotechnology Major Business
Table 85. Generex Biotechnology Peptide Cancer Vaccine Product and Services
Table 86. Generex Biotechnology Peptide Cancer Vaccine Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 87. Generex Biotechnology Recent Developments/Updates
Table 88. Generex Biotechnology Competitive Strengths & Weaknesses
Table 89. ISA Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 90. ISA Pharmaceuticals Major Business
Table 91. ISA Pharmaceuticals Peptide Cancer Vaccine Product and Services
Table 92. ISA Pharmaceuticals Peptide Cancer Vaccine Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 93. ISA Pharmaceuticals Recent Developments/Updates
Table 94. ISA Pharmaceuticals Competitive Strengths & Weaknesses
Table 95. OncoTherapy Science Basic Information, Manufacturing Base and Competitors
Table 96. OncoTherapy Science Major Business
Table 97. OncoTherapy Science Peptide Cancer Vaccine Product and Services
Table 98. OncoTherapy Science Peptide Cancer Vaccine Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 99. OncoTherapy Science Recent Developments/Updates
Table 100. OncoTherapy Science Competitive Strengths & Weaknesses
Table 101. Global Key Players of Peptide Cancer Vaccine Upstream (Raw Materials)
Table 102. Global Peptide Cancer Vaccine Typical Customers
LIST OF FIGURES
Figure 1. Peptide Cancer Vaccine Picture
Figure 2. World Peptide Cancer Vaccine Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Peptide Cancer Vaccine Total Revenue (2021-2032) & (USD Million)
Figure 4. World Peptide Cancer Vaccine Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World Peptide Cancer Vaccine Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company Peptide Cancer Vaccine Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company Peptide Cancer Vaccine Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company Peptide Cancer Vaccine Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company Peptide Cancer Vaccine Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company Peptide Cancer Vaccine Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company Peptide Cancer Vaccine Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company Peptide Cancer Vaccine Revenue (2021-2032) & (USD Million)
Figure 13. Peptide Cancer Vaccine Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Peptide Cancer Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 16. World Peptide Cancer Vaccine Consumption Value Market Share by Region (2021-2032)
Figure 17. United States Peptide Cancer Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 18. China Peptide Cancer Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe Peptide Cancer Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 20. Japan Peptide Cancer Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 21. South Korea Peptide Cancer Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN Peptide Cancer Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 23. India Peptide Cancer Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of Peptide Cancer Vaccine by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Peptide Cancer Vaccine Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Peptide Cancer Vaccine Markets in 2025
Figure 27. United States VS China: Peptide Cancer Vaccine Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Peptide Cancer Vaccine Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World Peptide Cancer Vaccine Market Size by Pipeline, (USD Million), 2021 & 2025 & 2032
Figure 30. World Peptide Cancer Vaccine Market Size Market Share by Pipeline in 2025
Figure 31. ITK-1
Figure 32. GRN-1201
Figure 33. TPIV200
Figure 34. TPIV110
Figure 35. UV1
Figure 36. Galinpepimut-S
Figure 37. TARP 27-35
Figure 38. HER-Vaxx
Figure 39. TARP 27-35
Figure 40. World Peptide Cancer Vaccine Market Size Market Share by Pipeline (2021-2032)
Figure 41. World Peptide Cancer Vaccine Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 42. World Peptide Cancer Vaccine Market Size Market Share by Application in 2025
Figure 43. Breast Cancer
Figure 44. Lung Cancer
Figure 45. Melanoma
Figure 46. Prostate Cancer
Figure 47. Others
Figure 48. World Peptide Cancer Vaccine Market Size Market Share by Application (2021-2032)
Figure 49. Peptide Cancer Vaccine Industrial Chain
Figure 50. Methodology
Figure 51. Research Process and Data Source
Figure 1. Peptide Cancer Vaccine Picture
Figure 2. World Peptide Cancer Vaccine Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Peptide Cancer Vaccine Total Revenue (2021-2032) & (USD Million)
Figure 4. World Peptide Cancer Vaccine Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World Peptide Cancer Vaccine Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company Peptide Cancer Vaccine Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company Peptide Cancer Vaccine Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company Peptide Cancer Vaccine Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company Peptide Cancer Vaccine Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company Peptide Cancer Vaccine Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company Peptide Cancer Vaccine Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company Peptide Cancer Vaccine Revenue (2021-2032) & (USD Million)
Figure 13. Peptide Cancer Vaccine Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Peptide Cancer Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 16. World Peptide Cancer Vaccine Consumption Value Market Share by Region (2021-2032)
Figure 17. United States Peptide Cancer Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 18. China Peptide Cancer Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe Peptide Cancer Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 20. Japan Peptide Cancer Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 21. South Korea Peptide Cancer Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN Peptide Cancer Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 23. India Peptide Cancer Vaccine Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of Peptide Cancer Vaccine by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Peptide Cancer Vaccine Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Peptide Cancer Vaccine Markets in 2025
Figure 27. United States VS China: Peptide Cancer Vaccine Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Peptide Cancer Vaccine Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World Peptide Cancer Vaccine Market Size by Pipeline, (USD Million), 2021 & 2025 & 2032
Figure 30. World Peptide Cancer Vaccine Market Size Market Share by Pipeline in 2025
Figure 31. ITK-1
Figure 32. GRN-1201
Figure 33. TPIV200
Figure 34. TPIV110
Figure 35. UV1
Figure 36. Galinpepimut-S
Figure 37. TARP 27-35
Figure 38. HER-Vaxx
Figure 39. TARP 27-35
Figure 40. World Peptide Cancer Vaccine Market Size Market Share by Pipeline (2021-2032)
Figure 41. World Peptide Cancer Vaccine Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 42. World Peptide Cancer Vaccine Market Size Market Share by Application in 2025
Figure 43. Breast Cancer
Figure 44. Lung Cancer
Figure 45. Melanoma
Figure 46. Prostate Cancer
Figure 47. Others
Figure 48. World Peptide Cancer Vaccine Market Size Market Share by Application (2021-2032)
Figure 49. Peptide Cancer Vaccine Industrial Chain
Figure 50. Methodology
Figure 51. Research Process and Data Source
